This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Citi Reaffirms Their Buy Rating on Zymeworks (ZYME)

Tipranks - Tipranks - Mon May 11, 8:44AM CDT

In a report released on May 8, Yigal Nochomovitz from Citi reiterated a Buy rating on Zymeworks, with a price target of $35.00. The company’s shares closed last Friday at $23.89.

Claim 55% Off TipRanks

Nochomovitz covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, ACADIA Pharmaceuticals, and Oric Pharmaceuticals. According to TipRanks, Nochomovitz has an average return of 8.1% and a 43.66% success rate on recommended stocks.

Currently, the analyst consensus on Zymeworks is a Strong Buy with an average price target of $39.89, representing a 66.97% upside. In a report released yesterday, LifeSci Capital also assigned a Buy rating to the stock with a $34.00 price target.

See the top stocks recommended by analysts >>

Based on Zymeworks’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.41 million and a GAAP net loss of $44.16 million. In comparison, last year the company earned a revenue of $27.11 million and had a GAAP net loss of $22.64 million

Read More on ZYME:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).